Pfizer Inc
Change company Symbol lookup
Select an option...
PFE Pfizer Inc
HSTRF Hollister Biosciences Inc
T AT&T Inc
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
MSFT Microsoft Corp
PEY Invesco High Yield Equity Dividend Achievers™ ETF
BAC Bank of America Corp
ARI Apollo Commercial Real Estate Finance Inc
ISNPY Intesa Sanpaolo SpA
BRKR Bruker Corp
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Closing Price
$36.55
Day's Change
0.07 (0.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
36.83
Day's Low
36.25
Volume
(Light)
Volume:
26,271,163

10-day average volume:
34,663,858
26,271,163

PFE's position in the Pharmaceuticals industry

Industry PeersPFEMRKLLYBMYRETA

Summary

Company ProfilePfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes...
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through...
Go to MRK summary
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include...
Go to LLY summary
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products...
Go to BMY summary
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of...
Go to RETA summary
52-Week Change

VS. INDUSTRY
-10.22%
-8.56%
45.98%
-3.45%
-45.18%
Market Cap

VS. INDUSTRY
$203.2B
$204.9B
$197.2B
$145.9B
$4.1B
Beta

VS. INDUSTRY
0.7
0.4
0.4
0.6
1.5
Dividend Yield

VS. INDUSTRY
4.27%
3.21%
1.65%
3.04%
--
P/E (TTM, GAAP)

VS. INDUSTRY
24.57x
17.81x
33.75x
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$48.6B
$47.3B
$23.2B
$39.4B
$8.5M
Profit Margin

VS. INDUSTRY
17.26%
24.47%
24.01%
-0.07%
-4,341.23%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
14.72%
-1.06%
17.37%
10.85%
--
Revenue Growth (TTM)

VS. INDUSTRY
-8.28%
3.00%
6.28%
62.97%
-73.69%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.